E2609
Phase 1Completed 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Early Alzheimer's Disease
Conditions
Early Alzheimer's Disease
Trial Timeline
Aug 1, 2016 โ Jan 25, 2017
NCT ID
NCT02859207About E2609
E2609 is a phase 1 stage product being developed by Eisai for Early Alzheimer's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02859207. Target conditions include Early Alzheimer's Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02859207 | Phase 1 | Completed |
| NCT01975636 | Phase 1 | Completed |
| NCT01716897 | Phase 1 | Completed |
Competing Products
20 competing products in Early Alzheimer's Disease